You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameUstekinumab
Accession NumberDB05679
TypeBiotech
GroupsApproved, Investigational
DescriptionCNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis.
Protein structureDb05679
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
CNTO-1275
Ustekinumab
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
StelaraSolution for injection in pre-filled syringe90 mgSubcutaneous useJanssen Cilag International Nv2009-01-16Not applicableEu
Stelarainjection, solution45 mg/.5mLsubcutaneousJanssen Biotech, Inc.2009-09-25Not applicableUs
StelaraSolution for injection45 mgSubcutaneous useJanssen Cilag International Nv2009-01-16Not applicableEu
Stelarainjection, solution90 mg/mLsubcutaneousJanssen Biotech, Inc.2009-09-25Not applicableUs
StelaraSolution for injection90 mgSubcutaneous useJanssen Cilag International Nv2009-01-16Not applicableEu
Stelarasolution45 mgsubcutaneousJanssen Inc2009-01-05Not applicableCanada
StelaraSolution for injection in pre-filled syringe45 mgSubcutaneous useJanssen Cilag International Nv2009-01-16Not applicableEu
Stelarasolution90 mgsubcutaneousJanssen Inc2013-01-07Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIFU77B4U5Z0
CAS numberNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in psoriasis and psoriatic disorders.
PharmacodynamicsNot Available
Mechanism of actionSimilar to the immunosuppressive function of Etanercept (Enbrel), CNTO 1275 is designed to interfere with the triggering of the body's inflamatory response through the suppression of certain cytokines. Specifically, CNTO 1275 blocks interleukin IL-12 and IL-23 (via the p40 subunit of IL-12 and IL-23) which help activate certain T-cells.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionsubcutaneous45 mg/.5mL
Injection, solutionsubcutaneous90 mg/mL
Solutionsubcutaneous45 mg
Solutionsubcutaneous90 mg
Solution for injectionSubcutaneous use45 mg
Solution for injectionSubcutaneous use90 mg
Solution for injection in pre-filled syringeSubcutaneous use45 mg
Solution for injection in pre-filled syringeSubcutaneous use90 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General References
  1. Wittig BM: Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Curr Opin Investig Drugs. 2007 Nov;8(11):947-54. [PubMed:17979029 ]
  2. Boker A, Kimball AB, Rolz-Cruz G: Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs. 2007 Nov;8(11):939-46. [PubMed:17979028 ]
  3. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U: Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007 May;247(1):1-11. Epub 2007 Aug 29. [PubMed:17761156 ]
External Links
ATC CodesL04AC05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
BelimumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Belimumab.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ustekinumab.
FingolimodUstekinumab may increase the immunosuppressive activities of Fingolimod.
InfliximabUstekinumab may increase the immunosuppressive activities of Infliximab.
LeflunomideThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Leflunomide.
NatalizumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Natalizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ustekinumab.
Rabies vaccineThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Rabies vaccine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Ustekinumab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ustekinumab.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Ustekinumab.
TofacitinibUstekinumab may increase the immunosuppressive activities of Tofacitinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Ustekinumab.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.Associates with IL23A to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in periphe...
Gene Name:
IL12B
Uniprot ID:
P29460
Molecular Weight:
37168.645 Da
References
  1. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U: Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007 May;247(1):1-11. Epub 2007 Aug 29. [PubMed:17761156 ]
  2. Wittig BM: Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Curr Opin Investig Drugs. 2007 Nov;8(11):947-54. [PubMed:17979029 ]
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:26 / Updated on September 27, 2016 10:59